WA-MARY-KAY
2.6.2022 22:55:07 CEST | Business Wire | Press release
Calling all models—your virtual runway awaits! Step & Repeat, the first ever style and fashion competition launched on TikTok, returns for season two on June 7. Last year, Glamhive and Mary Kay Global Design Studio unveiled the fashion reality contest that reached millions of users worldwide. Now, the four-week style challenge is back and promises to be the fashion extravaganza we’ve all been waiting for.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220602005868/en/
Celebrity Stylist Zadrian Smith (clients include: Ariana DeBose, Naama Preis, Naomi Scott) hosts Step & Repeat with three judges and industry favorites: celebrity stylist Tara Swennen (clients include: Kristen Stewart, Matthew McConaughey), celebrity stylist Nicole Chavez (clients include: Kristen Bell, Jessica Simpson), and celebrity hairstylist Larry Sims (clients include: Victoria Beckham, Queen Latifah).
Each week, host Zadrian Smith will announce a theme-based challenge for TikTok users to showcase their creativity through wardrobe, makeup, and hair. The show’s celebrity judges will duet the best looks from around the world and cast their votes for winners in each category. Participants are asked to incorporate the show’s custom sound, “Step & Repeat,” and hashtags, #stepandrepeat, #glamhive, and #marykay to enter their video into the competition. For each challenge there will be three winners, hand-picked by the judges, who will receive a cash prize plus an hour one-on-one meeting with an industry mentor.
At the end of the four weeks, Step & Repeat will announce one overall winner for each category, crowning them the very best in wardrobe, makeup, and hair based on entries from all over the world. TikTok is the place for anyone with talent and a creative voice to share their gift on a global scale. Step & Repeat is the platform that gives you the opportunity to be seen and celebrated.
Zadrian Smith, Celebrity Stylist (Host)
“As my career has progressed as a Global Fashion Director and Journalist, I’ve wanted to prioritize working to create a more equitable fashion industry. It’s not always easy or comfortable work, but any opportunity that I can provide to help other people interested in the industry with a step up - that’s a conversation that I want to be a part of.”
Tara Swennen, Celebrity Stylist (Judge)
“There are so many people with incredible creative talent and Step & Repeat gives them a place to shine. I'm very excited to see the looks that people from all over the world will be debuting on our social media runway!”
Nicole Chavez, Celebrity Stylist (Judge)
“Season One of ‘Step & Repeat’ absolutely inspired me. I was excited every week to see what the contestants created and blown away by the range of talent. I can't wait to see the results of our challenges in Season Two!”
Larry Sims, Celebrity Hairstylist (Judge)
“It takes courage, confidence, & creativity to show the world why you're an amazing artist. I’m excited to see the contestants bring it!”
Stephanie Sprangers, Founder and CEO of Glamhive
“Our vision for ‘Step & Repeat’ was to create a fast-paced style competition that encompassed creativity, inclusivity, connections, and recognition, and Season One delivered in spades. Now, for the second time, the industry's best are coming together to welcome and encourage style talent from around the world. We're so excited to see what happens in Season Two.”
Step & Repeat Mentors:
- Claire Sulmers, CEO & Founder of Fashion Bomb Daily
- Adam Drawas, Owner, Walker Drawas PR
- Quentin Thrash, Bespoke Designer & Celebrity Barber
- Brian Underwood, Fashion Director, Women’s Health
- Mandi Line, Costume Designer (The Bold Type, Pretty Little Liars, Shameless)
- Pandora Amoratis, Style Director, US Daily Mail
- Sheridan Ward, Celebrity Hairstylist
- Shatora Adrell, Fashion Designer and Stylist
- Carrie Colbert, Founding & General Partner, Curate Capital
- Quinn Murphy, Celebrity Makeup Artist
- Alexis Bennett, Editor, Vogue
- Gilda Koral Flora, Founder, Koral Communications
- Christian Wood, Celebrity Hairstylist
For more information, visit https://www.glamhive.com/tiktok
About Glamhive: Glamhive was founded by entrepreneur Stephanie Sprangers in 2017 with the vision to democratize personal styling and the premise that the confidence that comes with glamour should not be exclusive to the rich and famous. The online styling experience offers anyone with a WiFi connection access to stylists who will provide them with the support they need to be the best version of themselves. For stylists, it is a seamless end-to-end platform to help them grow their network and their business, 100% virtually.
About Mary Kay
One of the original glass ceiling breakers, Mary Kay Ash founded her dream beauty company in 1963 with one goal: enriching women’s lives. That dream has blossomed into a multibillion-dollar company with millions of independent sales force members in nearly 40 countries. As an entrepreneurship development company, Mary Kay is committed to empowering women on their journey through education, mentorship, advocacy, networking, and innovation. Mary Kay is dedicated to investing in the science behind beauty and manufacturing cutting-edge skincare, color cosmetics, nutritional supplements, and fragrances. Mary Kay believes in enriching lives today for a sustainable tomorrow, partnering with organizations from around the world focusing on promoting business excellence, supporting cancer research, advancing gender equality, protecting survivors from domestic abuse, beautifying our communities, and encouraging children to follow their dreams. Learn more at marykayglobal.com , find us on Facebook , Instagram , and LinkedIn , or follow us on Twitter .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220602005868/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom